Metraipolis › archive › dc_6a7b930d2d3f
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event… — Europe PMC PMID:41613782
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41613782
- DOI
- 10.3389/fphar.2026.1643906
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T19:42:18.729Z
- SHA-256 of the archived text
369cd08c0eec4ca7218a2219b9970bc49a85c29fc238f307694f1cdc528de9ca- Stable URL of this page
https://metraipolis.com/documento/dc_6a7b930d2d3f
How to cite
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event… — Europe PMC PMID:41613782 — Europe PMC (en), https://europepmc.org/article/MED/41613782 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6a7b930d2d3f (Metraipolis archive dc_6a7b930d2d3f, sha256 369cd08c0eec4ca7218a2219b9970bc49a85c29fc238f307694f1cdc528de9ca)
BibTeX
@misc{dc6a7b930d2d3f,
title = {Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event… — Europe PMC PMID:41613782},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41613782},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6a7b930d2d3f; sha256 369cd08c0eec4ca7218a2219b9970bc49a85c29fc238f307694f1cdc528de9ca},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41613782. Agents can read the archived copy with the MCP tool read_document.